In contrast, ME1 shows low expression levels in colorectal cancer (COAD), liver hepatocellular carcinoma (LIHC), lung squamous cell carcinoma (LUSC), adrenocortical carcinoma (ACC), acute myeloid leukemia (LAML), lower-grade glioma (LGG), ovarian cancer (OV), testicular germ cell tumors (TGCT), and other cancers, with statistically significant differences observed. This evidence concerns the gene ME1 and colon adenocarcinoma.